<p><strong>公司在 2026 年以重新焕发的商业动力和在美国和加拿大的关键商业任命进入新阶段</strong></p>
<p>温尼伯，曼尼托巴省，2026 年 2 月 12 日（环球新闻通讯社）——Kane Biotech Inc.（TSX-V:KNE）（“Kane Biotech”、“Kane” 或 “公司”）今天宣布其 revyve®抗菌伤口凝胶产品线在美国和加拿大恢复商业活动，并任命两位经验丰富的行业领袖推动北美的业务发展。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="175" height="227" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png"/></p>
<p><em>美国 FDA 510(k) 批准和加拿大卫生部批准的 revyve 抗菌伤口凝胶及 revyve 抗菌伤口凝胶喷雾</em></p>
<p><strong>在美国和加拿大的商业重启</strong>：</p>
<p>在美国，Kane 已与 Medstream Healthcare Solutions, LLC（佛罗里达州多瓦尔）和 Patient Care Medical（德克萨斯州奥斯汀）签署了非独占的分销/销售协议，预计近期将进行首次发货。</p>
<p>在加拿大，Kane 通过将与 Best Buy Medical Canada 的分销协议转换为非独占安排，恢复了商业活动，并开展了针对性的销售和取样活动。尽管迄今为止在两个国家的销售额并不显著，但这标志着 Kane 商业引擎的有意义重启。</p>
<p>“我们正在执行重置 Kane Biotech 的承诺，采用严谨的市场策略，” Kane Biotech 的临时首席执行官 Robert Huizinga 博士表示。“我们将继续生成科学信誉、临床验证，并以此为基础建立商业基础设施。”</p>
<p><strong>战略管理任命：</strong></p>
<p>为了支持这一增长阶段，Kane 任命了两位业务发展副总裁：</p>
<ul>
<li>Sherida (Kay) Watkins Weaver，美国业务发展副总裁。Kay 在伤口护理商业化方面拥有超过 20 年的经验，包括在 Omeza 和 Relevate Health 的领导角色。她在医疗系统、长期护理和家庭健康市场中领导市场准入、报销和采用策略。</li>
<li>Patti Burke-Martin，加拿大业务发展副总裁。Patti 是国家伤口护理领域的领导者，曾在 EO2 Concepts、Coloplast 和 ConvaTec 担任高级职务。她在建立高效团队和推动先进伤口护理技术在加拿大的采用方面有着良好的业绩记录。</li>
</ul>
<p>“Kay 和 Patti 在各自市场中带来了深厚的专业知识和可信赖的关系，” Huizinga 博士补充道。“他们的领导将对我们扩展分销网络和支持 revyve 的日益采用至关重要。”</p>
<p><strong>关于 Kane Biotech Inc.（TSX-V:KNE）</strong></p>
<p>Kane Biotech 正在商业化和开发新型伤口护理治疗方法，以破坏生物膜并改善愈合结果。生物膜是导致伤口抗生素耐药性的主要因素之一，造成严重的临床后果和显著的成本。revyve®同时针对生物膜和伤口细菌。revyve®抗菌伤口凝胶和 revyve®抗菌伤口凝胶喷雾已获得美国 FDA 510(k) 批准。revyve®抗菌伤口凝胶也获得了加拿大卫生部的批准。欲了解更多信息，请访问 revyvegel.com 或 revyvegel.ca。</p>
<p><strong>加入 Kane 的分销列表和社交媒体：</strong></p>
<p>要获取最新动态，请点击此处注册公司的电子邮件分销列表。</p>
<p><strong>关注 Kane</strong></p>
<p><strong>网站：</strong> kanebiotech.com</p>
<p><strong>LinkedIn：</strong> https://www.linkedin.com/company/kanebiotech/</p>
<p><strong>演示文稿：</strong> https://kanebiotech.com/publications-posters/</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Robert Huizinga</strong> 临时首席执行官<br/>Kane Biotech Inc.<br/>rhuizinga@kanebiotech.com<br/>(780) 970-1100</td>
<td><strong>Ray Dupuis</strong> 首席财务官<br/>Kane Biotech Inc.<br/>rdupuis@kanebiotech.com<br/>(204) 298-2200</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><em>无论是 TSX 风险投资交易所还是其监管服务提供者（该术语在 TSX 风险投资交易所的政策中有定义）均不对本公告的充分性或准确性承担责任。</em></p>
<p><em>关于前瞻性信息的警告</em></p>
<p><em>本新闻稿包含关于 Kane Biotech Inc.的某些声明，这些声明构成适用证券法下的前瞻性信息。这些声明反映了管理层当前的信念，并基于目前可用的信息。某些重要因素或假设在做出前瞻性声明时被应用，实际结果可能与这些声明中表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于与公司的相关风险：（a）财务状况，包括迄今为止缺乏显著收入和对股权及其他融资的依赖；（b）业务，包括其早期发展阶段、政府监管、产品市场接受度、快速技术变革和对关键人员的依赖；（c）知识产权，包括公司保护其知识产权的能力和对其战略合作伙伴的依赖；以及（d）资本结构，包括其普通股不支付股息、普通股市场价格的波动性和上市公司成本。有关这些及其他风险和不确定性的更多信息，请参阅公司向适用证券监管机构提交的披露文件，详见 www.sedarplus.ca。公司警告上述可能影响未来结果的因素列表并非</em> <em>详尽无遗。</em></p>
<p>本公告附带的照片可在</p>
<p>https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16VTBPU00zTkRJeU1qY3dJekl3T1RBMU5EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16VTBPU00zTkRJeU1qY3dJekl3T1RBMU5EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png"/></p>

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

<p>Kane Biotech Inc. 已在美国和加拿大恢复其 revyve® 抗菌伤口凝胶的商业活动，并任命了两位经验丰富的领导者以增强业务发展。该公司已在美国签署了分销协议，并将其在加拿大的协议转换为非独占安排。临时首席执行官 Dr. Robert Huizinga 强调了以有序的市场策略重置公司的重要性。新任副总裁 Kay Watkins Weaver 和 Patti Burke-Martin 带来了丰富的伤口护理商业化经验。Kane Biotech 旨在通过其产品解决生物膜问题并改善愈合效果</p>

<p><strong>Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada</strong></p>
<div class="lb-trans"><p><strong>公司在 2026 年以重新焕发的商业动力和在美国和加拿大的关键商业任命进入新阶段</strong></p>
</div><p>WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America.</p>
<div class="lb-trans"><p>温尼伯，曼尼托巴省，2026 年 2 月 12 日（环球新闻通讯社）——Kane Biotech Inc.（TSX-V:KNE）（“Kane Biotech”、“Kane” 或 “公司”）今天宣布其 revyve®抗菌伤口凝胶产品线在美国和加拿大恢复商业活动，并任命两位经验丰富的行业领袖推动北美的业务发展。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png"/></p>
<p><em>US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray</em></p>
<div class="lb-trans"><p><em>美国 FDA 510(k) 批准和加拿大卫生部批准的 revyve 抗菌伤口凝胶及 revyve 抗菌伤口凝胶喷雾</em></p>
</div><p><strong>Commercial Restart in the U.S. and Canada</strong>:</p>
<div class="lb-trans"><p><strong>在美国和加拿大的商业重启</strong>：</p>
</div><p>In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, FL) and Patient Care Medical (Austin, TX) with initial shipments expected in the near term.</p>
<div class="lb-trans"><p>在美国，Kane 已与 Medstream Healthcare Solutions, LLC（佛罗里达州多瓦尔）和 Patient Care Medical（德克萨斯州奥斯汀）签署了非独占的分销/销售协议，预计近期将进行首次发货。</p>
</div><p>In Canada, Kane has resumed commercial activity by converting its distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement, along with targeted sales and sampling initiatives. While sales to date in both countries are not material, they mark a meaningful restart of Kane’s commercial engine.</p>
<div class="lb-trans"><p>在加拿大，Kane 通过将与 Best Buy Medical Canada 的分销协议转换为非独占安排，恢复了商业活动，并开展了针对性的销售和取样活动。尽管迄今为止在两个国家的销售额并不显著，但这标志着 Kane 商业引擎的有意义重启。</p>
</div><p>“We are executing on our commitment to reset Kane Biotech using a disciplined market approach,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure.”</p>
<div class="lb-trans"><p>“我们正在执行重置 Kane Biotech 的承诺，采用严谨的市场策略，” Kane Biotech 的临时首席执行官 Robert Huizinga 博士表示。“我们将继续生成科学信誉、临床验证，并以此为基础建立商业基础设施。”</p>
</div><p><strong>Strategic Management Appointments:</strong></p>
<div class="lb-trans"><p><strong>战略管理任命：</strong></p>
</div><p>To support this next phase of growth, Kane has appointed two Vice Presidents of Business Development:</p>
<div class="lb-trans"><p>为了支持这一增长阶段，Kane 任命了两位业务发展副总裁：</p>
</div><ul>
<li>Sherida (Kay) Watkins Weaver, Vice President of Business Development, United States. Kay brings over 20 years of experience in wound care commercialization, including leadership roles at Omeza and Relevate Health. She has led market access, reimbursement, and adoption strategies across health systems, long-term care, and home health markets.</li>
<li>Patti Burke-Martin, Vice President of Business Development, Canada. Patti is a national wound care leader with senior roles at EO2 Concepts, Coloplast, and ConvaTec. She has a proven track record in building high-performing teams and driving adoption of advanced wound care technologies across Canada.</li>
</ul>
<div class="lb-trans"><ul>
<li>Sherida (Kay) Watkins Weaver，美国业务发展副总裁。Kay 在伤口护理商业化方面拥有超过 20 年的经验，包括在 Omeza 和 Relevate Health 的领导角色。她在医疗系统、长期护理和家庭健康市场中领导市场准入、报销和采用策略。</li>
<li>Patti Burke-Martin，加拿大业务发展副总裁。Patti 是国家伤口护理领域的领导者，曾在 EO2 Concepts、Coloplast 和 ConvaTec 担任高级职务。她在建立高效团队和推动先进伤口护理技术在加拿大的采用方面有着良好的业绩记录。</li>
</ul>
</div><p>“Kay and Patti bring deep expertise and trusted relationships in their respective markets,” added Dr. Huizinga. “Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve.”</p>
<div class="lb-trans"><p>“Kay 和 Patti 在各自市场中带来了深厚的专业知识和可信赖的关系，” Huizinga 博士补充道。“他们的领导将对我们扩展分销网络和支持 revyve 的日益采用至关重要。”</p>
</div><p><strong>About Kane Biotech Inc. (TSX-V:KNE)</strong></p>
<div class="lb-trans"><p><strong>关于 Kane Biotech Inc.（TSX-V:KNE）</strong></p>
</div><p>Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are U.S. FDA 510(k) cleared. revyve® Antimicrobial Wound Gel is also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.</p>
<div class="lb-trans"><p>Kane Biotech 正在商业化和开发新型伤口护理治疗方法，以破坏生物膜并改善愈合结果。生物膜是导致伤口抗生素耐药性的主要因素之一，造成严重的临床后果和显著的成本。revyve®同时针对生物膜和伤口细菌。revyve®抗菌伤口凝胶和 revyve®抗菌伤口凝胶喷雾已获得美国 FDA 510(k) 批准。revyve®抗菌伤口凝胶也获得了加拿大卫生部的批准。欲了解更多信息，请访问 revyvegel.com 或 revyvegel.ca。</p>
</div><p><strong>Join Kane’s Distribution List &amp; Social Media:</strong></p>
<div class="lb-trans"><p><strong>加入 Kane 的分销列表和社交媒体：</strong></p>
</div><p>To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.</p>
<div class="lb-trans"><p>要获取最新动态，请点击此处注册公司的电子邮件分销列表。</p>
</div><p><strong>Follow Kane</strong></p>
<div class="lb-trans"><p><strong>关注 Kane</strong></p>
</div><p><strong>Website:</strong> kanebiotech.com</p>
<div class="lb-trans"><p><strong>网站：</strong> kanebiotech.com</p>
</div><p><strong>LinkedIn:</strong> https://www.linkedin.com/company/kanebiotech/</p>
<div class="lb-trans"><p><strong>LinkedIn：</strong> https://www.linkedin.com/company/kanebiotech/</p>
</div><p><strong>Presentations:</strong> https://kanebiotech.com/publications-posters/</p>
<div class="lb-trans"><p><strong>演示文稿：</strong> https://kanebiotech.com/publications-posters/</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>For more information:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Robert Huizinga</strong> Interim CEO<br/>Kane Biotech Inc.<br/>rhuizinga@kanebiotech.com<br/>(780) 970-1100</td>
<td><strong>Ray Dupuis</strong> Chief Financial Officer<br/>Kane Biotech Inc.<br/>rdupuis@kanebiotech.com<br/>(204) 298-2200</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Robert Huizinga</strong> 临时首席执行官<br/>Kane Biotech Inc.<br/>rhuizinga@kanebiotech.com<br/>(780) 970-1100</td>
<td><strong>Ray Dupuis</strong> 首席财务官<br/>Kane Biotech Inc.<br/>rdupuis@kanebiotech.com<br/>(204) 298-2200</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p><em>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</em></p>
<div class="lb-trans"><p><em>无论是 TSX 风险投资交易所还是其监管服务提供者（该术语在 TSX 风险投资交易所的政策中有定义）均不对本公告的充分性或准确性承担责任。</em></p>
</div><p><em>Caution Regarding Forward-Looking Information</em></p>
<div class="lb-trans"><p><em>关于前瞻性信息的警告</em></p>
</div><p><em>This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not</em> <em>exhaustive.</em></p>
<div class="lb-trans"><p><em>本新闻稿包含关于 Kane Biotech Inc.的某些声明，这些声明构成适用证券法下的前瞻性信息。这些声明反映了管理层当前的信念，并基于目前可用的信息。某些重要因素或假设在做出前瞻性声明时被应用，实际结果可能与这些声明中表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于与公司的相关风险：（a）财务状况，包括迄今为止缺乏显著收入和对股权及其他融资的依赖；（b）业务，包括其早期发展阶段、政府监管、产品市场接受度、快速技术变革和对关键人员的依赖；（c）知识产权，包括公司保护其知识产权的能力和对其战略合作伙伴的依赖；以及（d）资本结构，包括其普通股不支付股息、普通股市场价格的波动性和上市公司成本。有关这些及其他风险和不确定性的更多信息，请参阅公司向适用证券监管机构提交的披露文件，详见 www.sedarplus.ca。公司警告上述可能影响未来结果的因素列表并非</em> <em>详尽无遗。</em></p>
</div><p>A photo accompanying this announcement is available at</p>
<div class="lb-trans"><p>本公告附带的照片可在</p>
</div><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40</p>
<div class="lb-trans"><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16VTBPU00zTkRJeU1qY3dJekl3T1RBMU5EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1MzU0OSM3NDIyMjcwIzIwOTA1NDI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png"/></p>

Kane Biotech Restarts Commercial Activities and Strengthens North American Management | KNBIF Stock News

StockTitan

标普全球医疗股指数 ETF - iShares

Jyong Biotech Ltd.

动态生物技术与基因组 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

2 倍做多纳斯达克生物技术 ETF - ProShares

NKGen Biotech

Kane Biotech 重新启动商业活动并加强其在北美的管理 | KNBIF 股票新闻